<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403117</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 5350</org_study_id>
    <secondary_id>DA09236</secondary_id>
    <nct_id>NCT00403117</nct_id>
  </id_info>
  <brief_title>Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana</brief_title>
  <official_title>Opioid Antagonism Enhances Marijuana's Effects in Heavy Marijuana Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the subjective effects of marijuana will be
      decreased by low-doses (&lt; 25 mg) of naltrexone and increased by high-doses (&gt; 50 mg) of
      naltrexone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laboratory animal studies demonstrate that endogenous cannabinoids and opioids are closely
      inter-related. We have completed a series of studies in marijuana smokers showing that a
      clinically-utilized dose of naltrexone (50 mg) enhanced the reinforcing and subjective
      effects of orally-administered tetrahydrocannabinol (THC), while a low naltrexone dose (12
      mg) blunted the effects of THC. A better understanding of the effects of a range of
      naltrexone doses in combination with smoked marijuana has important implications for the
      following reasons: (1) Alcohol- and opioid-dependent patients receive high doses of
      naltrexone (50-150 mg), which may increase the abuse liability of marijuana, (2) Low-dose
      naltrexone blunts THC's intoxicating effects, suggesting potential utility as a treatment
      medication for marijuana dependence. This study will determine if naltrexone (0, 12, 25, 50,
      100 mg) administration 45 min prior to marijuana administration (0, 3.27% THC) alters
      marijuana's subjective, cognitive or physiological effects. Marijuana smokers will spend
      approximately 5h/day for a total of 10 days in the outpatient laboratory. Participants will
      visit the outpatient laboratory 2-3 times per week, with a minimum 48-hr interval between
      sessions to allow for naltrexone clearance. These data will provide important information
      regarding the clinical use of naltrexone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Subjective Mood Scores as a Function of Marijuana Strength and Naltrexone Dose.</measure>
    <time_frame>Baseline compared to 6 week timepoint</time_frame>
    <description>All subjective effects were measured using visual analog scales (VAS), a series of 100 mm long lines labeled 'not at all' at one end (0 mm) and 'extremely' at the other end (100 mm). Participants were instructed to rate their subjective experiences on the line according to how they felt at that particular moment. Subjective assessments included measures of perceived marijuana strength, marijuana &quot;high&quot;, &quot;good effects&quot; of marijuana, and how much marijuana was &quot;liked&quot;.
Marijuana's effects were determined by comparing the active and inactive marijuana conditions when paired with the placebo naltrexone condition (one comparison). Naltrexone's intrinsic effects were assessed by comparing placebo and each active dose of naltrexone (12, 25, 50, and 100 mg) under the inactive marijuana condition (four comparisons). Finally, the active marijuana- placebo naltrexone condition was compared to the active marijuana-active naltrexone conditions (four comparisons)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mean Psychomotor Task Performance as a Function of Marijuana Strength and Naltrexone Dose</measure>
    <time_frame>Baseline compared to 6 week timepoint</time_frame>
    <description>Change in Digit Symbol Substitution Test (DSST) scores. Increasing scores indicate improvement, on a scale of 0-90.
The task batteries included total correct attempts on a 3-min DSST.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mean Heart Rate as a Function of Marijuana Strength and Naltrexone Dose.</measure>
    <time_frame>Baseline compared to 6 week timepoint</time_frame>
    <description>Change in mean heart rate as a function of marijuana and naltrexone dose</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Marijuana Use</condition>
  <arm_group>
    <arm_group_label>Placebo, Marijuana (0% THC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Marijuana (3.27% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (12mg), Marijuana (0% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (12mg), Marijuana (3.27% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (25mg), Marijuana (0% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (25mg), Marijuana (3.27% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (50mg), Marijuana (0% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (50mg), Marijuana (3.27% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (100mg), Marijuana (0% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (100mg), Marijuana (3.27% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Inactive Marijuana (0% THC)</intervention_name>
    <description>One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.</description>
    <arm_group_label>Placebo, Marijuana (0% THC)</arm_group_label>
    <other_name>treatment type 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Active Marijuana (3.27% THC)</intervention_name>
    <description>One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.</description>
    <arm_group_label>Placebo, Marijuana (3.27% THC)</arm_group_label>
    <other_name>treatment type 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 12 Mg+ Active Marijuana (3.27% THC)</intervention_name>
    <description>One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.</description>
    <arm_group_label>Naltrexone (12mg), Marijuana (3.27% THC)</arm_group_label>
    <other_name>Treatment type 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 25 Mg + Active Marijuana (3.27% THC)</intervention_name>
    <description>One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.</description>
    <arm_group_label>Naltrexone (25mg), Marijuana (3.27% THC)</arm_group_label>
    <other_name>treatment type 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 50 Mg+ Active Marijuana (3.27% THC)</intervention_name>
    <description>One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.</description>
    <arm_group_label>Naltrexone (50mg), Marijuana (3.27% THC)</arm_group_label>
    <other_name>treatment type 5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 100 Mg+ Active Marijuana (3.27% THC)</intervention_name>
    <description>One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.</description>
    <arm_group_label>Naltrexone (100mg), Marijuana (3.27% THC)</arm_group_label>
    <other_name>treatment type 6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 12 Mg + Inactive Marijuana (0% THC)</intervention_name>
    <description>One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.</description>
    <arm_group_label>Naltrexone (12mg), Marijuana (0% THC)</arm_group_label>
    <other_name>treatment type 7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 25 Mg + Inactive Marijuana (0% THC)</intervention_name>
    <description>One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.</description>
    <arm_group_label>Naltrexone (25mg), Marijuana (0% THC)</arm_group_label>
    <other_name>treatment type 8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 50 Mg + Inactive Marijuana (0% THC)</intervention_name>
    <description>One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.</description>
    <arm_group_label>Naltrexone (50mg), Marijuana (0% THC)</arm_group_label>
    <other_name>treatment type 9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 100 Mg + Inactive Marijuana (0% THC)</intervention_name>
    <description>One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.</description>
    <arm_group_label>Naltrexone (100mg), Marijuana (0% THC)</arm_group_label>
    <other_name>treatment type 10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current marijuana use

          -  Able to perform study procedures

          -  21-45 years of age

          -  Women practicing an effective form of birth control

        Exclusion Criteria:

          -  Current, repeated illicit drug use (other than marijuana)

          -  Presence of significant medical illness (e.g., diabetes, cardiovascular disease,
             hypertension, examination, laboratory hepatitis, clinically significant laboratory
             abnormalities, tests, 12-lead ECG, Mantoux test LFTs &gt; 3x upper limit of normal)

          -  History of heart disease

          -  Request for drug treatment

          -  Current parole or probation

          -  Pregnancy or current lactation

          -  Recent history of significant violent behavior

          -  Previous adverse reaction to naltrexone

          -  Major current Axis I psychopathology Psychiatric interview (e.g., major depressive
             disorder, bipolar disorder, suicide risk, schizophrenia)

          -  Current use of any prescription or over-the-counter medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2006</study_first_posted>
  <results_first_submitted>August 7, 2017</results_first_submitted>
  <results_first_submitted_qc>November 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2017</results_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Naltrexone</keyword>
  <keyword>Smoked Marijuana</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 15 males and 14 females completed this study, which used a within-subject design such that each participant received 10 different drug treatments/interventions in total.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study Participant Flow</title>
          <description>Of the 49 participants enrolled, only 29 completed all 10 drug interventions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Number of Baseline Participants</title>
          <description>Baseline measures are only reported for the 29 participants who completed the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Subjective Mood Scores as a Function of Marijuana Strength and Naltrexone Dose.</title>
        <description>All subjective effects were measured using visual analog scales (VAS), a series of 100 mm long lines labeled ‘not at all’ at one end (0 mm) and ‘extremely’ at the other end (100 mm). Participants were instructed to rate their subjective experiences on the line according to how they felt at that particular moment. Subjective assessments included measures of perceived marijuana strength, marijuana &quot;high&quot;, &quot;good effects&quot; of marijuana, and how much marijuana was &quot;liked&quot;.
Marijuana's effects were determined by comparing the active and inactive marijuana conditions when paired with the placebo naltrexone condition (one comparison). Naltrexone's intrinsic effects were assessed by comparing placebo and each active dose of naltrexone (12, 25, 50, and 100 mg) under the inactive marijuana condition (four comparisons). Finally, the active marijuana– placebo naltrexone condition was compared to the active marijuana–active naltrexone conditions (four comparisons)</description>
        <time_frame>Baseline compared to 6 week timepoint</time_frame>
        <population>Data from 29 participants were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Marijuana (0.0%THC)</title>
            <description>Placebo + Marijuana (0.0%THC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Marijuana (3.27% THC)</title>
            <description>Placebo + Marijuana (3.27% THC)</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone (12mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone (12mg) + marijuana (0.0%THC)</description>
          </group>
          <group group_id="O4">
            <title>Naltrexone (12mg) + Marijuana (3.27%THC)</title>
            <description>Naltrexone (12mg) + marijuana (3.27%THC)</description>
          </group>
          <group group_id="O5">
            <title>Naltrexone (25mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone (25mg) + marijuana (0.0%THC)</description>
          </group>
          <group group_id="O6">
            <title>Naltrexone (25mg) + Marijuana (3.27%THC)</title>
            <description>Naltrexone (25mg) + marijuana (3.27%THC)</description>
          </group>
          <group group_id="O7">
            <title>Naltrexone (50mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone (50mg) + marijuana (0.0%THC)</description>
          </group>
          <group group_id="O8">
            <title>Naltrexone (50mg) + Marijuana (3.27%THC)</title>
            <description>Naltrexone (50mg) + marijuana (3.27%THC)</description>
          </group>
          <group group_id="O9">
            <title>Naltrexone (100mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone (100mg) + marijuana (0.0%THC)</description>
          </group>
          <group group_id="O10">
            <title>Naltrexone (100mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Subjective Mood Scores as a Function of Marijuana Strength and Naltrexone Dose.</title>
          <description>All subjective effects were measured using visual analog scales (VAS), a series of 100 mm long lines labeled ‘not at all’ at one end (0 mm) and ‘extremely’ at the other end (100 mm). Participants were instructed to rate their subjective experiences on the line according to how they felt at that particular moment. Subjective assessments included measures of perceived marijuana strength, marijuana &quot;high&quot;, &quot;good effects&quot; of marijuana, and how much marijuana was &quot;liked&quot;.
Marijuana's effects were determined by comparing the active and inactive marijuana conditions when paired with the placebo naltrexone condition (one comparison). Naltrexone's intrinsic effects were assessed by comparing placebo and each active dose of naltrexone (12, 25, 50, and 100 mg) under the inactive marijuana condition (four comparisons). Finally, the active marijuana– placebo naltrexone condition was compared to the active marijuana–active naltrexone conditions (four comparisons)</description>
          <population>Data from 29 participants were included in this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean VAS ratings &quot;Marijuana Strength&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="0.8"/>
                    <measurement group_id="O2" value="25.0" spread="3.2"/>
                    <measurement group_id="O3" value="6.7" spread="0.9"/>
                    <measurement group_id="O4" value="34.0" spread="2.1"/>
                    <measurement group_id="O5" value="8.1" spread="0.6"/>
                    <measurement group_id="O6" value="31.6" spread="1.1"/>
                    <measurement group_id="O7" value="9.7" spread="0.7"/>
                    <measurement group_id="O8" value="36.2" spread="2.3"/>
                    <measurement group_id="O9" value="10.1" spread="0.9"/>
                    <measurement group_id="O10" value="34.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean VAS ratings &quot;High&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.7"/>
                    <measurement group_id="O2" value="11.0" spread="1.1"/>
                    <measurement group_id="O3" value="3.7" spread="0.6"/>
                    <measurement group_id="O4" value="23.0" spread="3.2"/>
                    <measurement group_id="O5" value="3.0" spread="0.6"/>
                    <measurement group_id="O6" value="20.4" spread="2.2"/>
                    <measurement group_id="O7" value="4.0" spread="0.3"/>
                    <measurement group_id="O8" value="22.2" spread="1.7"/>
                    <measurement group_id="O9" value="3.9" spread="0.3"/>
                    <measurement group_id="O10" value="21.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean VAS ratings &quot;Good Effect&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="1.1"/>
                    <measurement group_id="O2" value="38.3" spread="4.5"/>
                    <measurement group_id="O3" value="6.8" spread="1.2"/>
                    <measurement group_id="O4" value="43.1" spread="5.7"/>
                    <measurement group_id="O5" value="9.0" spread="0.8"/>
                    <measurement group_id="O6" value="44.1" spread="5.0"/>
                    <measurement group_id="O7" value="10.2" spread="1.1"/>
                    <measurement group_id="O8" value="42.2" spread="4.2"/>
                    <measurement group_id="O9" value="12.5" spread="0.9"/>
                    <measurement group_id="O10" value="44.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean VAS ratings &quot;Like Drug&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="1.2"/>
                    <measurement group_id="O2" value="35.0" spread="5.3"/>
                    <measurement group_id="O3" value="7.0" spread="0.7"/>
                    <measurement group_id="O4" value="44.0" spread="3.7"/>
                    <measurement group_id="O5" value="9.3" spread="1.2"/>
                    <measurement group_id="O6" value="34.7" spread="4.8"/>
                    <measurement group_id="O7" value="10.3" spread="0.5"/>
                    <measurement group_id="O8" value="38.0" spread="6.6"/>
                    <measurement group_id="O9" value="11.4" spread="1.2"/>
                    <measurement group_id="O10" value="44.0" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Psychomotor Task Performance as a Function of Marijuana Strength and Naltrexone Dose</title>
        <description>Change in Digit Symbol Substitution Test (DSST) scores. Increasing scores indicate improvement, on a scale of 0-90.
The task batteries included total correct attempts on a 3-min DSST.</description>
        <time_frame>Baseline compared to 6 week timepoint</time_frame>
        <population>Data from 29 participants were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Marijuana (0.0%THC)</title>
            <description>Placebo Inactive marijuana (0.0% THC)
Naltrexone: During each session, one capsule containing placebo or naltrexone (12, 25, 50, and 100 mg) was administered to the participant in a size 00 opaque capsules with lactose filler, prepared by the New York State Psychiatric Institute Research Pharmacy. A marijuana cigarette (0 or 3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse was smoked 45 min after naltrexone administration, the time at which naltrexone levels peak.
Marijuana: During each session, one capsule containing placebo or naltrexone (12, 25, 50, and 100 mg) was administered to the participant in a size 00 opaque capsules with lactose filler, prepared by the New York State Psychiatric Institute Research Pharmacy. A marijuana cigarette (0 or 3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse was smoked 45 min after naltrexone administration, the time at which naltrexone levels peak.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Marijuana (3.27% THC)</title>
            <description>Placebo marijuana (3.27% THC)
Naltrexone: During each session, one capsule containing placebo or naltrexone (12, 25, 50, and 100 mg) was administered to the participant in a size 00 opaque capsules with lactose filler, prepared by the New York State Psychiatric Institute Research Pharmacy. A marijuana cigarette (0 or 3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse was smoked 45 min after naltrexone administration, the time at which naltrexone levels peak.
Marijuana: During each session, one capsule containing placebo or naltrexone (12, 25, 50, and 100 mg) was administered to the participant in a size 00 opaque capsules with lactose filler, prepared by the New York State Psychiatric Institute Research Pharmacy. A marijuana cigarette (0 or 3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse was smoked 45 min after naltrexone administration, the time at which naltrexone levels peak.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone (12mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone + Inactive marijuana</description>
          </group>
          <group group_id="O4">
            <title>Naltrexone (12mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
          <group group_id="O5">
            <title>Naltrexone (25mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone + Inactive marijuana</description>
          </group>
          <group group_id="O6">
            <title>Naltrexone (25mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
          <group group_id="O7">
            <title>Naltrexone (50mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone + Inactive marijuana</description>
          </group>
          <group group_id="O8">
            <title>Naltrexone (50mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
          <group group_id="O9">
            <title>Naltrexone (100mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone + Inactive marijuana</description>
          </group>
          <group group_id="O10">
            <title>Naltrexone (100mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Psychomotor Task Performance as a Function of Marijuana Strength and Naltrexone Dose</title>
          <description>Change in Digit Symbol Substitution Test (DSST) scores. Increasing scores indicate improvement, on a scale of 0-90.
The task batteries included total correct attempts on a 3-min DSST.</description>
          <population>Data from 29 participants were included in this analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" spread="1.8"/>
                    <measurement group_id="O2" value="86.1" spread="1.7"/>
                    <measurement group_id="O3" value="86.7" spread="1.7"/>
                    <measurement group_id="O4" value="84.7" spread="1.6"/>
                    <measurement group_id="O5" value="83.4" spread="1.7"/>
                    <measurement group_id="O6" value="83.5" spread="1.6"/>
                    <measurement group_id="O7" value="83.6" spread="1.8"/>
                    <measurement group_id="O8" value="82.1" spread="1.4"/>
                    <measurement group_id="O9" value="82.1" spread="1.6"/>
                    <measurement group_id="O10" value="83.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Heart Rate as a Function of Marijuana Strength and Naltrexone Dose.</title>
        <description>Change in mean heart rate as a function of marijuana and naltrexone dose</description>
        <time_frame>Baseline compared to 6 week timepoint</time_frame>
        <population>A total of 29 participants were included in the final analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Marijuana (0.0%THC)</title>
            <description>Placebo Inactive marijuana (0.0% THC)
Naltrexone: During each session, one capsule containing placebo or naltrexone (12, 25, 50, and 100 mg) was administered to the participant in a size 00 opaque capsules with lactose filler, prepared by the New York State Psychiatric Institute Research Pharmacy. A marijuana cigarette (0 or 3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse was smoked 45 min after naltrexone administration, the time at which naltrexone levels peak.
Marijuana: During each session, one capsule containing placebo or naltrexone (12, 25, 50, and 100 mg) was administered to the participant in a size 00 opaque capsules with lactose filler, prepared by the New York State Psychiatric Institute Research Pharmacy. A marijuana cigarette (0 or 3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse was smoked 45 min after naltrexone administration, the time at which naltrexone levels peak.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Marijuana (3.27% THC)</title>
            <description>Placebo marijuana (3.27% THC)
Naltrexone: During each session, one capsule containing placebo or naltrexone (12, 25, 50, and 100 mg) was administered to the participant in a size 00 opaque capsules with lactose filler, prepared by the New York State Psychiatric Institute Research Pharmacy. A marijuana cigarette (0 or 3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse was smoked 45 min after naltrexone administration, the time at which naltrexone levels peak.
Marijuana: During each session, one capsule containing placebo or naltrexone (12, 25, 50, and 100 mg) was administered to the participant in a size 00 opaque capsules with lactose filler, prepared by the New York State Psychiatric Institute Research Pharmacy. A marijuana cigarette (0 or 3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse was smoked 45 min after naltrexone administration, the time at which naltrexone levels peak.</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone (12mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone + Inactive marijuana</description>
          </group>
          <group group_id="O4">
            <title>Naltrexone (12mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
          <group group_id="O5">
            <title>Naltrexone (25mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone + Inactive marijuana</description>
          </group>
          <group group_id="O6">
            <title>Naltrexone (25mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
          <group group_id="O7">
            <title>Naltrexone (50mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone + Inactive marijuana</description>
          </group>
          <group group_id="O8">
            <title>Naltrexone (50mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
          <group group_id="O9">
            <title>Naltrexone (100mg) + Marijuana (0.0%THC)</title>
            <description>Naltrexone + Inactive marijuana</description>
          </group>
          <group group_id="O10">
            <title>Naltrexone (100mg) + Marijuana (3.27%THC)</title>
            <description>naltrexone + active marijuana</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Heart Rate as a Function of Marijuana Strength and Naltrexone Dose.</title>
          <description>Change in mean heart rate as a function of marijuana and naltrexone dose</description>
          <population>A total of 29 participants were included in the final analysis</population>
          <units>Heart rate (beats/minute)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="0.5"/>
                    <measurement group_id="O2" value="70.7" spread="0.6"/>
                    <measurement group_id="O3" value="65.8" spread="0.5"/>
                    <measurement group_id="O4" value="72.1" spread="0.4"/>
                    <measurement group_id="O5" value="67.3" spread="0.4"/>
                    <measurement group_id="O6" value="72.7" spread="0.7"/>
                    <measurement group_id="O7" value="65.6" spread="0.3"/>
                    <measurement group_id="O8" value="72.2" spread="0.6"/>
                    <measurement group_id="O9" value="67.7" spread="0.4"/>
                    <measurement group_id="O10" value="72.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the six weeks that each participant was enrolled in the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Inactive Marijuana (0.0%THC)</title>
          <description>In this arm, participants received placebo + inactive marijuana (0.0%THC)</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Marijuana (3.27% THC)</title>
          <description>In this arm, participants received placebo + Marijuana (3.27% THC)</description>
        </group>
        <group group_id="E3">
          <title>Naltrexone (12mg) + Marijuana (0.0%THC)</title>
          <description>In this arm, participants received naltrexone (12mg) + marijuana (0.0%THC)</description>
        </group>
        <group group_id="E4">
          <title>Naltrexone (12mg) + Marijuana (3.27%THC)</title>
          <description>In this arm, participants received naltrexone (12mg) + marijuana (3.27%THC)</description>
        </group>
        <group group_id="E5">
          <title>Naltrexone (25mg) + Marijuana (0.0%THC)</title>
          <description>In this arm, participants received naltrexone (25mg) + marijuana (0.0%THC)</description>
        </group>
        <group group_id="E6">
          <title>Naltrexone (25mg) + Marijuana (3.27%THC)</title>
          <description>In this arm, participants received naltrexone (25mg) + marijuana (3.27%THC)</description>
        </group>
        <group group_id="E7">
          <title>Naltrexone (50mg) + Marijuana (0.0%THC)</title>
          <description>In this arm, participants received naltrexone (50mg) + marijuana (0.0%THC)</description>
        </group>
        <group group_id="E8">
          <title>Naltrexone (50mg) + Marijuana (3.27%THC)</title>
          <description>In this arm, participants received naltrexone (50mg) + marijuana (3.27%THC)</description>
        </group>
        <group group_id="E9">
          <title>Naltrexone (100mg) + Marijuana (0.0%THC)</title>
          <description>In this arm, participants received naltrexone (100mg) + marijuana (0.0%THC)</description>
        </group>
        <group group_id="E10">
          <title>Naltrexone (100mg) + Marijuana (3.27%THC)</title>
          <description>In this arm, participants received naltrexone (100mg) + marijuana (3.27%THC)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal upset</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>conflicting social circumstance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of this study is the small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret Haney, PhD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6153</phone>
      <email>mh235@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

